Biological impact assessment of nanomaterial used in nanomedicine. Introduction to the NanoTEST project

References

• Baun A, Hansen SF. 2008. Environmental challenges for nanomedicine. Nanomedicine 3:605–608
   PubMed Web of Science ®Google Scholar
• Borak B, Biernat P, Prescha A, Baszczuk A, Pluta J. 2012. In vivo study on the biodistribution of silica particles in the bodies of rats. Adv Clin Exp Med 21:13–18
   PubMed Web of Science ®Google Scholar
• Borm PJ, Müller-Schulte D. 2006. Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nanomed 1:235–224
   PubMed Web of Science ®Google Scholar
• Bosi S, Feruglio L, Da Ros T, Spalluto G, Gregoretti B, Terdoslavich M, et al. 2004. Hemolytic effects of water-soluble fullerene derivatives. J Med Chem 47:6711–6715
   PubMed Web of Science ®Google Scholar
• Boulaiz H, Alvarez PJ, Ramirez A, Marchal JA, Prados J, Rodríguez-Serrano F, et al. 2011. Nanomedicine: application areas and development prospects. Int J Mol Sci 12:3303–3321
   PubMed Web of Science ®Google Scholar
• Bouwmeester H, Lynch I, Marvin HJ, Dawson KA, Berges M, Braguer D, et al. 2011. Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology 1–1:11
   Google Scholar
• Brook RD, Rajagopalan S, Pope CA, Brook JR, Bhatnagar A, Diez-Roux AV, et al. 2010. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 121:2331–2378
   PubMed Web of Science ®Google Scholar
• Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. 2010. Time evolution of the nanoparticle protein Corona. ACS Nano 4:3623–3632
   PubMed Web of Science ®Google Scholar
• DIRECTIVE 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. http://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf. Accessed on 04 February 2013
   Google Scholar
• DIRECTIVE 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0034:0057:EN:PDF. Accessed on 04 February 2013
   Google Scholar
• Dobrovolskaia MA, McNeil SE. 2007. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2:469–478
   PubMed Web of Science ®Google Scholar
• Dusinska M, Fjellsbø LM, Magdolenova Z, Ravnum S, Rinna A, Runden-Pran E. 2011. Chapter 11: safety of nanomaterial in nanomedicine. In: Hunter RJ, Preedy VR, editors. Nanomedicine in health and disease. New Hampshire: CRC Press. pp 203–226
   Google Scholar
• Dusinska M, Magdolenova Z, Fjellsbø LM. 2013. Toxicological aspects for nanomaterial in humans. Chapter 1: nanotechnology for nucleic acid delivery. In: Oupicky D, Ogris M, editors. Methods in molecular biology. Vol. 948. New York: Humana Press. pp 1–12
   Google Scholar
• Dusinska M, Rundén-Pran E, Carreira SC, Saunders M. 2012. In vitro and in vivo toxicity test methods. Chapter 4: critical evaluation of toxicity tests. In: Fadeel B, Pietroiusti A, Shvedova A, editors. Adverse effects of engineered nanomaterials: exposure, toxicology and impact on human health. Elsevier, NY, USA. pp 63–84
   Google Scholar
• Dusinska M; the NanoTEST Consortium. 2009. Testing strategies for the safety of nanoparticles used in medical application. Nanomedicine 4:605–607
   PubMed Web of Science ®Google Scholar
• Duvall MN. editor. 2012. FDA regulation on nanotechnology. pp 1–135. http://www.shb.com/newsevents/2012/FDARegulationofNanotechnology.pdf
   Google Scholar
• Dziendzikowska K, Gromadzka-Ostrowska J, Lankoff A, Oczkowski M, Krawczyńska A, Chwastowska J, et al. 2012. Time-dependent biodistribution and excretion of silver nanoparticles in male Wistar rats. J Appl Toxicol 32:920–928 European Comission. Nanomaterials http://ec.europa.eu/environment/chemicals/nanotech/index.htm
   PubMed Web of Science ®Google Scholar
• EFSA. 2009. Scientific opinion of the scientific committee on a request from the European commission on the potential risks arising from nanoscience and nanotechnologies on food and feed safety. EFSA J 958:1–39
   Google Scholar
• EFSA. 2011. Guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. EFSA J 9:2140; 1-36
   Google Scholar
• EU directive 1223/2009 REGULATION (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products Official Journal of the European Union L 342/75. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:342:0059:0209:en:PDF
   Google Scholar
• FDA. 2010. Center for drug evaluation and research, office of pharmaceutical science, reporting format for nanotechnology-related information in cmc review, manual of policies and procedures 5015.9. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM214304.pdf
   Google Scholar
• FDA. 2012. Code of Federal Regulations, Title 21, volume 5, Food and Drugs, Chapter 1 Food and Drug Administration Department of Health and Human Services Subchapter D – Drugs for human use (part 312) investigational new drug applications. [21CFR312 revised as of April 1,2012]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1
   Google Scholar
• Godin B, Driessen WH, Proneth B, Lee SY, Srinivasan S, Rumbaut R, et al. 2010. An integrated approach for the rational design of nanovectors for biomedicalimaging and therapy. Adv Genet 69:31–64
   PubMed Web of Science ®Google Scholar
• Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. 2011. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 44:979–989
   PubMed Web of Science ®Google Scholar
• Handy RD, Henry TB, Scown TM, Johnstone BD, Tyler CR. 2008b. Manufactured nanoparticles: their uptake and effects on fish – a mechanistic analysis. Ecotoxicology 17:396–409
   PubMed Web of Science ®Google Scholar
• Handy RD, von der Kammer F, Lead JR, Hassellöv M, Owen R, Crane M. 2008a. The ecotoxicology and chemistry of manufactured nanoparticles. Ecotoxicology 17:287–314
   PubMed Web of Science ®Google Scholar
• Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schäffler M, et al. 2011. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 77:407–416
   PubMed Web of Science ®Google Scholar
• ISO. 2006a. 14040: Environmental management – Life cycle assessment – Principles and framework
   Google Scholar
• ISO. 2006b. 14044: Environmental management – Life cycle assessment – Requirement and guidelines
   Google Scholar
• Juillerat-Jeanneret L. 2006. Critical analysis of cancer therapy using nanomaterials. In: Kumar CSSR, editor. Nanomaterials for cancer therapy and diagnosis. Vol. 6. Serie: nanotechnologies for life sciences. WILEY-VCH Verlag; Weinheim, Germany. pp 199–232
   Google Scholar
• Klaine SJ, Koelmans AA, Horne N, Carley S, Handy RD, Kapustka L, et al. 2012. Paradigms to assess the environmental impact of manufactured nanomaterials. Environ Toxico Chem 31:3–14
   PubMed Web of Science ®Google Scholar
• Kreyling WG, Semmler-Behnke M, Chaudhry Q. 2010. A complementary definition of nanomaterial. Nano Today 5:165–168
   Web of Science ®Google Scholar
• Lai D. 2012. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward. WIREs Nanomed Nanobiotechnol 4:1–15
   Google Scholar
• Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. 2011. Theranostic nanomedicine. Acc Chem Res 44:1029–1038
   PubMed Web of Science ®Google Scholar
• Lundqvist M, Stigler J, Cedervall T, Berggård T, Flanagan MB, Lynch I, et al. 2011. The evolution of the protein Corona around nanoparticles: a test study. ACS Nano 5:7503–7509
   PubMed Web of Science ®Google Scholar
• Malkiewicz K, Hansson SO, Ruden C. 2009. Assessment factors for extrapolation from short-time to chronic exposure–are the REACH guidelines adequate? Toxicol Lett 190:16–22
   PubMed Web of Science ®Google Scholar
• Milani S, Baldelli Bombelli F, Pitek AS, Dawson KA, Rädler J. 2012. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard Corona. ACS Nano 6:2532–2541
   PubMed Web of Science ®Google Scholar
• Mills NL, Amin N, Robinson SD, Anand A, Davies J, Patel D, et al. 2006. Do inhaled carbon nanoparticles translocate directly into the circulation in humans? Am J Respir Crit Care Med 173:426–431
   PubMed Web of Science ®Google Scholar
• Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, et al. 2011. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 133:2525–2534
   PubMed Web of Science ®Google Scholar
• Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. 2013. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 166:182–194
   PubMed Web of Science ®Google Scholar
• Nel A, Xia T, Meng H, Wang X, Lin S, Ji Z, et al. 2013. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Acc Chem Res (Mar 19) 46(3):607–21
   PubMed Web of Science ®Google Scholar
• Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, et al. 2004. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16:437–445
   PubMed Web of Science ®Google Scholar
• OECD. 2013. Directorate for Science, Technology and Industry Committee for Scientific and Technological Policy Working Party on Nanotechnology, Regulatory Frameworks for Nanotechnology in Foods and Medical products. Summary results of a survey activity. DSTI/STP/NANO(2012)22/FINAL. 1–51. http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&docLanguage=En
   Google Scholar
• Pablico-Lansigan MH, Situ SF, Samia AC. 2013. Magnetic particle imaging: advancements and perspectives for real-time in vivo monitoring and image-guided therapy. Nanoscale 5:4040–4055
   PubMed Web of Science ®Google Scholar
• Patel VR, Agrawal YK. 2011. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res 2:81–87
   PubMedGoogle Scholar
• Pautler M, Brenner S. 2010. Nanomedicine: promises and challenges for the future of public health. Int J Nanomed 5:803–809
   PubMed Web of Science ®Google Scholar
• REGULATION (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF. Accessed 04 Ferburay 2013
   Google Scholar
• SCCS. 2012. Guidance on the safety assessment of nanomaterials in cosmetics (SCCS/1484/12). http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_s_005.pdf
   Google Scholar
• SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). 2009. Risk assessment of products of nanotechnologies. 1–71. http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf
   Google Scholar
• SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). 2012. Request for a scientific opinion: Health effects of nanomaterials used in Medical Devices. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_q_032.pdf
   Google Scholar
• SCENIHR (Scientific Committee on Emerging and Newly-Identified Health Risks). 2007. The appropriateness of the risk assessment methodology in accordance with the Technical Guidance Documents for new and existing substances for assessing the risks of nanomaterials http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_003b.pdf
   Google Scholar
• SCHER (Scientific Committees on Health and Environmental Risks). 2013. Emerging and Newly Identified Health Risks SCENIHR, Consumer Safety SCCS. Addressing the New Challenges for Risk Assessment. 1–157. http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_131.pdf
   Google Scholar
• Schrand AM, Dai L, Schlager JJ, Hussain SM. 2012. Toxicity testing of nanomaterials. Adv Experim Med Biol 745:58–75
   PubMed Web of Science ®Google Scholar
• Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker MNanoImpactNet Consortium. 2013a. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) 8:449–67
   PubMed Web of Science ®Google Scholar
• Schütz CA, Juillerat-Jeanneret L, Soltmann C, Müller H. 2013b. Toxicity data of therapeutic nanoparticles in patent documents. World Patent Information 35:110–14
   Google Scholar
• Sebekova K, Dusinska M, Simon Klenovics K, Kollarova R, Boor P, Kebis A, et al. 2014. Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultrasmall superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats. Nanotoxicology 8:142–157
   PubMed Web of Science ®Google Scholar
• Setyan A, Sauvain JJ, Guillemin M, Riediker M, Demirdjian B, Rossi MJ. 2010. Probing functional groups at the gas-aerosol interface using heterogeneous titration reactions: a tool for predicting aerosol health effects? ChemPhysChem 11:3823–3835
   PubMed Web of Science ®Google Scholar
• Som C, Berges M, Chaudhry Q, Dusinska M, Fernandes TF, Olsen SI, et al. 2010. The importance of life cycle concepts for the development of safe nanoproducts. Toxicology 269:160–169
   PubMed Web of Science ®Google Scholar
• Stone V, Nowack B, Baun A, van den Brink N, von der Kammer F, Dusinska M, et al. 2010. Nanomaterials for environmental studies: classification, reference material issues, and strategies for physico-chemical characterization. Sci Total Environ 408:1745–1754
   PubMed Web of Science ®Google Scholar
• Teow Y, Asharani PV, Hande MP, Valiyaveettil S. 2011. Health impact and safety of engineered nanomaterials. Chem Commun 47:7025–7038
   PubMed Web of Science ®Google Scholar
• Tosi G, Vergoni AV, Ruozi B, Bondioli L, Badiali L, Rivasi F, et al. 2010. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release 145:49–57
   PubMed Web of Science ®Google Scholar
• Volkovova K, Handy RD, Ulicna O, Kucharská J, Staruchova M, Kebis A, et al. 2015. Health effects of selected nanoparticlesin vivo: Liver function and hepatotoxicity following intravenous injection of TiO2 or iron nanoparticles in rodents. Nanotoxicology 9(S1):95–105
   PubMed Web of Science ®Google Scholar
• Warheit DB, Borm PJA, Hennes C, Jurgen L. 2007. Testing strageties to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal Toxicol 19:631–643
   PubMed Web of Science ®Google Scholar